Author: admin

Northern Comfort Launches New Financing Program to Ease HVAC Costs

Northern Comfort introduces a 12-month, no-payment financing option with 0% same-as-cash terms to help homeowners and businesses manage rising expenses for HVAC repair, service, and installation amid economic challenges.

Northern Comfort announced a new financing program designed to ease the financial impact of essential heating and cooling services amid rising costs. The program, which offers “No Payments for 12 Months” and 0% same-as-cash financing regardless of credit history, is available for homeowners and businesses across Algonquin, Barrington, Cary, Crystal Lake, Lake Barrington, Palatine, and Wauconda.

The financing option comes as inflation, tariffs, and taxes contribute to increased costs for HVAC repair, HVAC service, and HVAC installation. Northern Comfort says the program is intended to help customers access quality heating and cooling systems without the burden of high upfront payments.

“We recognize that many households and businesses are facing tighter budgets,” said Thomas Gilhooly, CEO and founder of Northern Comfort. “Our new financing program is structured to remove the initial cost barrier, allowing our customers to upgrade their systems while managing their cash flow more effectively.”

Northern Comfort, which has been serving Northwest Chicagoland since 2009, noted that the initiative is designed to support routine maintenance needs as well as larger projects. The company will continue to offer its full range of services, including HVAC repair, HVAC service, and HVAC installation. As part of the program, customers receive a 10-year parts and labor warranty, providing long-term protection for their investment.

The company, known for its service throughout the region, is also reinforcing its commitment to quality and reliability. Northern Comfort’s technicians are licensed, bonded, and insured, ensuring that work is completed according to industry standards. The firm emphasizes that the new financing program does not compromise on service or safety.

In addition to the financing option, Northern Comfort is focused on maintaining strong community ties. “Our aim is to make necessary heating and cooling services accessible to everyone, no matter the circumstances,” Gilhooly said. “We are working to provide reliable solutions for HVAC repair, HVAC service, and HVAC installation while keeping the needs of our local communities in focus.”

The new program has already received attention in the local market, with many customers expressing interest in the opportunity to delay payments while still accessing needed services. Northern Comfort expects that the financing program will not only help manage current economic challenges but also support long-term energy efficiency improvements for its customers.

Northern Comfort invites those in need of HVAC repair, HVAC service, or HVAC installation to learn more about the financing program by visiting their website or contacting their customer service team. The company remains committed to ensuring that reliable and efficient climate control solutions remain within reach for residents and businesses in Northwest Chicagoland.

About Northern Comfort

Founded in 2009, Northern Comfort is a family-owned HVAC company based in Lake Barrington, Ill. The company provides a full range of services including HVAC repair, HVAC service, and HVAC installation across Northwest Chicagoland. Northern Comfort is dedicated to delivering reliable solutions that meet the practical needs of its customers.

Media Contact
Company Name: Northern Comfort
Contact Person: Dakota Marks
Email: Send Email
Country: United States
Website: https://northerncomfort.net/

Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Bile Duct Cancer (Cholangiocarcinoma) Pipeline Insight” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape. It covers the Bile Duct Cancer (Cholangiocarcinoma) pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bile Duct Cancer (Cholangiocarcinoma) therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report to explore emerging therapies, key Bile Duct Cancer (Cholangiocarcinoma) Companies, and future Bile Duct Cancer (Cholangiocarcinoma) treatment landscapes @ Bile Duct Cancer (Cholangiocarcinoma) Pipeline Outlook Report

Key Takeaways from the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report

  • In February 2025:- Servier Affaires Medicales:- A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA). All patients who meet inclusion criteria will be enrolled to receive ivosidenib tablets orally once daily for 28 day cycles, continuing as long as clinical benefit and consent for participation is maintained.
  • In February 2025:- Eisai Co. Ltd:- The primary purpose of the study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed gemcitabine-based combination chemotherapy.
  • In February 2025:- Taiho Oncology Inc.:- This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
  • In February 2025:- Medivir:- This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.
  • In February 2025:- Bold Therapeutics Inc.:- BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
  • In February 2025:- Seagen Inc.:- This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer. It will also look at whether tucatinib works with these drugs to treat certain types of cancer.
  • In February 2025:- Apollo Therapeutics Ltd.:- This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
  • In February 2025:- Janssen Research & Development LLC:- The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with non-small-cell lung cancer (NSCLC), urothelial cancer, esophageal cancer and cholangiocarcinoma.
  • In February 2025:- PureTech:- A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors. This is an open-label, uncontrolled, multicenter Phase 1/2 study with a dose escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed/refractory metastatic solid tumors.
  • DelveInsight’s Bile Duct Cancer (Cholangiocarcinoma) pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Bile Duct Cancer (Cholangiocarcinoma) treatment.
  • The leading Bile Duct Cancer (Cholangiocarcinoma) Companies such as Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
  • Promising Bile Duct Cancer (Cholangiocarcinoma) Therapies such as GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.

Discover how the Bile Duct Cancer (Cholangiocarcinoma) treatment paradigm is evolving. Access DelveInsight’s in-depth Bile Duct Cancer (Cholangiocarcinoma) Pipeline Analysis for a closer look at promising breakthroughs @ Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials and Studies

Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs Profile

  • TT-00420: TransThera Biosciences

TT-00420 is an innovative, global phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of TT-00420 to be efficacious in various solid tumors. It was granted the Orphan-Drug Designation and Fast Track Designation by the FDA for the treatment of CCA. In July 2023, TT-00420 was granted the Breakthrough Therapy Designation (BTD) by NMPA in China.

  • VG161: Virogin Biotech

VG161, Virogin’s pioneering oncolytic virus built on the company’s proprietary SynerlyticTM Platform, is an attenuated herpes simplex virus type 1 (HSV-1) armed with multiple payloads of IL12 & IL15/IL15Ra and a unique PD-L1 blocking peptide. The neurovirulence of wild-type HSV-1 is mitigated by the deletion of ICP 34.5 gene. These payloads can synergistically stimulate both innate and adaptive anti-tumor immunity in the tumor microenvironment. VG161 has been confirmed to be safe and effective in many tumor xenograft mouse models and in GLP toxicity studies preclinically. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cholangiocarcinoma.

  • NXP800: Nuvectis Pharma

NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator. NXP800 is also being evaluated in an investigator-initiated study conducted in collaboration with the Mayo Clinic for the treatment of cholangiocarcinoma, an indication for which the FDA granted NXP800 Orphan Drug Designation. The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA. NXP800 completed a Phase 1a dose-escalation study in the first half of 2023. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Cholangiocarcinoma.

The Bile Duct Cancer (Cholangiocarcinoma) pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Bile Duct Cancer (Cholangiocarcinoma) with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bile Duct Cancer (Cholangiocarcinoma) Treatment.
  • Bile Duct Cancer (Cholangiocarcinoma) Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Bile Duct Cancer (Cholangiocarcinoma) Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bile Duct Cancer (Cholangiocarcinoma) market.

Get a detailed analysis of the latest innovations in the Bile Duct Cancer (Cholangiocarcinoma) pipeline. Explore DelveInsight’s expert-driven report today! @ Bile Duct Cancer (Cholangiocarcinoma) Unmet Needs

Bile Duct Cancer (Cholangiocarcinoma) Companies

Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.

Bile Duct Cancer (Cholangiocarcinoma) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Bile Duct Cancer (Cholangiocarcinoma) Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Bile Duct Cancer (Cholangiocarcinoma) Therapies and key Bile Duct Cancer (Cholangiocarcinoma) Developments @ Bile Duct Cancer (Cholangiocarcinoma) Market Drivers and Barriers, and Future Perspectives

Scope of the Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report

  • Coverage- Global
  • Bile Duct Cancer (Cholangiocarcinoma) Companies- Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
  • Bile Duct Cancer (Cholangiocarcinoma) Therapies- GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
  • Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Bile Duct Cancer (Cholangiocarcinoma) Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Bile Duct Cancer (Cholangiocarcinoma) drug development? Find out in DelveInsight’s exclusive Bile Duct Cancer (Cholangiocarcinoma) Pipeline Report—access it now! @ Bile Duct Cancer (Cholangiocarcinoma) Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Bile Duct Cancer (Cholangiocarcinoma): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Bile Duct Cancer (Cholangiocarcinoma)– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. TT-00420: TransThera Biosciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. VG161: Virogin Biotech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. NXP800: Nuvectis Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Bile Duct Cancer (Cholangiocarcinoma) Key Companies
  21. Bile Duct Cancer (Cholangiocarcinoma) Key Products
  22. Bile Duct Cancer (Cholangiocarcinoma)- Unmet Needs
  23. Bile Duct Cancer (Cholangiocarcinoma)- Market Drivers and Barriers
  24. Bile Duct Cancer (Cholangiocarcinoma)- Future Perspectives and Conclusion
  25. Bile Duct Cancer (Cholangiocarcinoma) Analyst Views
  26. Bile Duct Cancer (Cholangiocarcinoma) Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bile Duct Cancer (Cholangiocarcinoma) Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Drone Simulator Market Projected to Reach USD 143.5 Billion by 2032, Growing at a 15% CAGR Due to Rising Demand in Commercial and Military Sectors

Drone Simulator Market Research Report Information by Component (Software and Hardware), by Device Type (Fixed and Portable), by Drone Type (Fixed-Wing and Multi-Rotor), by Technology (Augmented Reality and Virtual Reality), by End-User (Commercial and Military), and by Region (North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America) – Forecast till 2032

Global Drone Simulator Market Outlook

The drone simulator market size is experiencing significant growth, driven by the increasing adoption of drones across various sectors and the necessity for effective pilot training solutions. According to Market Research Future, the global drone simulator market is projected to reach approximately USD 143.5 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15% from 2024 to 2032.

Drone Simulator Market Key Players

The key players in the global drone simulator market are Aegis Technologies (US), CAE Inc. (Canada), General Atomics (US), Havelsan AS (Turkey), Israel Aerospace Industries Ltd (Israel), L3 Link Training & Simulation (UK), Leonardo SpA (Italy), Sikan Nutzfahrzeuge GmbH (Germany), Simlat Uas Simulation (Israel), Singapore Technologies Electronics Limited (Singapore), and Zen Technologies Limited (India).

Get a Quote – Request a price quote for the report or specific research services.

Drone Simulator Industry Developments

February 2025: Real Drone Simulator (RDS): The upcoming version of RDS is set to introduce a User Profile system, requiring users to register for a free RDS account to access the software. This update aims to enhance user experience by incorporating numerous new features, including additional drones, parts, and real-world maps based on 3D-scanned environments.

Liftoff Simulator: On January 22, 2025, Liftoff released update 0.7.3, adding the innovative 3D-printed, foldable long-range drone, the Micro Fold, to the Liftoff: Micro Drones fleet. This update reflects Liftoff’s commitment to integrating cutting-edge drone designs into their simulation platform.

Drone Racing League Simulator (DRL Sim): The DRL Sim continues to be a premier choice for enthusiasts aiming to master drone racing or refine high-speed flying skills. Priced at USD 10, it offers an outstanding, step-by-step training program, a plethora of maps, a track editor, and community-generated content, making it ideal for beginners.

VelociDrone FPV Simulator: VelociDrone remains a top-tier FPV simulator featuring online multiplayer, single-player, and offline multiplayer game modes. With over 40 available sceneries and tens of thousands of tracks, it provides a comprehensive platform for both racing and freestyle flying.

Market Segmentation

The drone simulator market is segmented based on components, device types, drone types, technologies, end-users, and regions.

  • Component: The market comprises software and hardware components. Software solutions offer virtual environments for pilot training, while hardware includes physical equipment like control systems and simulation rigs.
  • Device Type: Simulators are categorized into fixed and portable devices. Fixed simulators provide comprehensive training setups, whereas portable simulators offer flexibility and on-site training capabilities.
  • Drone Type: The market includes fixed-wing and multi-rotor drones. Fixed-wing drones are primarily used for long-distance and endurance missions, while multi-rotor drones are favored for versatility and maneuverability.
  • Technology: Technological segmentation covers augmented reality (AR) and virtual reality (VR). AR integrates virtual elements into real-world settings, enhancing situational awareness, while VR provides immersive, fully virtual training environments.
  • End-User: The primary end-users are commercial and military sectors. Commercial applications encompass industries like agriculture, real estate, and media, whereas the military sector utilizes drones for surveillance, reconnaissance, and combat operations.

Regional Analysis

Geographically, the drone simulator market spans North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America.

  • North America: This region holds a significant market share due to technological advancements and substantial investments in drone technology. The presence of key industry players further propels market growth.
  • Europe: European countries are increasingly adopting drone simulators for commercial applications, particularly in sectors like agriculture and infrastructure inspection.
  • Asia-Pacific: Rapid industrialization and the integration of drones in various industries contribute to the market’s expansion in this region. Countries like China and India are notable contributors.
  • Middle East & Africa and Latin America: These regions are gradually embracing drone technology, with growing investments in both commercial and military applications.

Market Drivers

Several factors are propelling the growth of the drone simulator market:

  • Increased Drone Adoption: Drones are becoming integral in industries such as agriculture, real estate, and media for tasks like crop monitoring, aerial photography, and infrastructure inspection. This surge necessitates proficient pilots, thereby boosting the demand for simulators.
  • Cost-Effective Training: Simulators offer a safe and economical platform for pilots to practice and hone their skills without the risks associated with real-flight training.
  • Technological Advancements: The integration of AR and VR technologies has enhanced the realism and effectiveness of drone simulators, making training more immersive and efficient.
  • Regulatory Support: Governments worldwide are formulating policies to integrate drones into commercial airspace, which includes mandating comprehensive pilot training programs, further driving the simulator market.

Buy Now – Take immediate action to purchase the full report and access all the valuable information it contains.

Challenges

Despite the positive outlook, the market faces certain challenges:

  • High Initial Investment: The development and deployment of advanced simulators require substantial capital, which can be a barrier for small and medium-sized enterprises.
  • Rapid Technological Changes: The fast-paced evolution of drone technology necessitates continuous updates and upgrades to simulation systems, posing a challenge for manufacturers and users alike.

Future Outlook

The drone simulator market is poised for robust growth in the coming years. As drone applications expand across various sectors, the need for skilled operators will rise, subsequently increasing the demand for advanced training solutions. Manufacturers are expected to focus on developing more sophisticated and user-friendly simulators, incorporating cutting-edge technologies to enhance training efficacy.

In conclusion, the drone simulator market presents substantial growth opportunities, driven by technological advancements, increasing drone adoption, and supportive regulatory frameworks. Stakeholders in this market are well-positioned to capitalize on these trends by offering innovative and effective training solutions to meet the evolving needs of drone operators worldwide.

Frequently Asked Questions (FAQ):

How the Drone Simulator Market is Worth Globally?

Drone Simulator Market it is estimated to grow at a CAGR of 15% By 2024–2032In Which Region drone simulator Industry Growing

North America was the largest regional market due to the high adoption rate of drone simulators in the US and Canada

 

Discover More Research Reports on Aerospace & Defence by Market Research Future

Military Aircraft Avionics Market Research Report – Global Forecast till 2030

Airborne ISR Market Research Report – Global Forecast to 2030

Maritime Security Market Research Report – Global Forecast till 2030

Aircraft Synthetic Vision System Market Report Information Global Forecast to 2030

Non-Lethal Weapons Market Report Information Forecast to 2030

Aircraft Aftermarket Parts Market Research Report Global Forecast till 2030

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor New York,

10013 United States of America+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: info@marketresearchfuture.com

Follow Us: LinkedIn | Twitter

Website: https://www.marketresearchfuture.com/

https://www.wiseguyreports.com/

https://www.wantstats.com/

 

 

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Drone Simulator Market Projected to Reach USD 143.5 Billion by 2032, Growing at a 15% CAGR Due to Rising Demand in Commercial and Military Sectors

Kenwood Management Company Completes 9800 SF Lease With Straughan Environmental in Columbia, Maryland

Kenwood Quarry LLC, an affiliate of Kenwood Management Company, a mid-Atlantic commercial property owner-manager, announced today that it had completed a 9,800 sf, 7-year lease with Straughan Environmental, a leading engineering and environmental firm advancing sustainable & resilient communities.

Kenwood was represented by Charles Breitenother and Austin Eber from KLNB. Straughan was represented by Scott Matthews from Cushman & Wakefield.

Straughan, an award-winning environmental engineering firm is committed to developing sustainable solutions by considering the social, economic, and natural environments while challenging standard approaches and considering unique applications of emerging technologies. Straughan engineers strive to demonstrate that sustainable solutions are the better option for fiscal responsibility, long-term resiliency, and community satisfaction.

Located at 9175 Guilford Road in Columbia, Maryland, Kenwood purchased Quarry Pond Overlook in 2021. The three-story office building overlooks a large quarry, which is surrounded by mature trees. The office building also features a large deck overlooking the pond for tenants to enjoy. Conveniently located off of Maryland Route 32 and sandwiched between Maryland Route 29 and Interstate I-95, Quarry Pond Overlook is also near Fort Meade.

Commercial Interior Construction has been awarded a contract to improve the space for Straughan. They are expected to occupy their new corporate headquarters in June.

Tom Driscoll, Asset Manager from Kenwood, said, ”We are very excited to welcome Straughan to Quarry Pond Overlook. The property’s unique setting is a perfect match with Straughan’s company goals to promote sustainable work environments.”

Quarry Pond Overlook currently has two suites available. One is 868 sf and the other is 9186 sf, which can be subdivided.

About Kenwood Management

Kenwood Management is a privately held owner-operator of a 1.4 million square foot portfolio of office, medical, flex, and warehouse properties in the Washington, D.C., and Baltimore markets. With a unique private equity model, Kenwood combines its own sponsor equity with investments from high-net-worth individuals, enabling co-investors to participate in long-term, stable, cash-flowing commercial real estate opportunities.

Headquartered in Bethesda, MD, Kenwood has been delivering consistent investment performance for over 25 years. The company’s success is driven by its disciplined acquisition strategy, focusing on multi-tenant properties in prime locations that provide diversification, reduced vacancy risks, and reliable cash flow.

For more information about Kenwood Management and its investment opportunities, visit www.kenwoodmgt.com.

Media Contact
Company Name: Kenwood Management Company
Contact Person: Bill Singer
Email: Send Email
Country: United States
Website: https://www.kenwoodmgt.com/

Pest Control Services in Chester Now Offered by Affordable Pest Solutions LLC

Pest Control Services in Chester Now Offered by Affordable Pest Solutions LLC

Chester, NJ – Affordable Pest Solutions LLC, a family-owned and operated pest control company, is proud to announce the expansion of its comprehensive pest control services to Chester, New Jersey. With a focus on effective, affordable, and environmentally conscious pest management, the company aims to address the diverse pest control needs of Chester residents and businesses.

Affordable Pest Solutions LLC brings years of expertise to Chester’s pest control landscape. The company’s founder, Seth, a licensed pest control professional with extensive experience since 2014, leads a team of skilled specialists dedicated to creating pest-free environments for clients.

“Our approach to pest control in Chester is rooted in thorough inspections, targeted treatments, and ongoing monitoring,” states Seth Shaljian, founder of Affordable Pest Solutions LLC. “We understand the unique pest challenges faced by Chester residents and businesses, and we’re committed to providing tailored solutions that effectively eliminate and prevent pest infestations.”

The company’s service offerings encompass a wide range of pest control solutions, including their signature Yearly 365 Protection Plan. This comprehensive service creates a protective barrier against pests, ensuring year-round prevention and control. Affordable Pest Solutions LLC specializes in managing various pest issues, including rodent control, ant infestations, spider problems, and stinging insect removal.

In addition to general pest control, the company offers specialized services such as termite treatment, wood-destroying insect control, and wood-destroying insect reports (WDIR). These services are particularly crucial for Chester’s homeowners and real estate transactions, providing peace of mind and protecting property values.

Affordable Pest Solutions LLC emphasizes the importance of professional pest management over do-it-yourself methods. Their team of exterminators utilizes safe, effective, and eco-friendly pest control products and techniques. This approach ensures the elimination of pests while prioritizing the safety of families, pets, and the environment.

The company’s pest control methods involve a comprehensive three-step approach: inspection and identification, treatment and extermination, and prevention and maintenance. This systematic process allows for the development of targeted pest management plans tailored to each client’s specific needs.

For commercial clients in Chester, Affordable Pest Solutions LLC offers customized pest control programs designed to meet the unique requirements of businesses. These services help maintain sanitary conditions, protect reputations, and ensure compliance with health regulations.

Affordable Pest Solutions LLC is known for its commitment to customer satisfaction, offering flexible scheduling options and free estimates for their services. The company also provides veteran and senior discounts, making professional pest control services more accessible to the Chester community.

As Affordable Pest Solutions LLC expands its services to Chester, residents and businesses can expect reliable, effective, and affordable pest control solutions. The company’s dedication to using the latest techniques and products in pest management positions them as a valuable resource in maintaining pest-free environments throughout Chester.

For more information about pest control services in Chester, please contact Seth Shaljian at +19732299547.

About Affordable Pest Solutions LLC:

Affordable Pest Solutions LLC is a locally owned and operated pest control company serving Northwest New Jersey. Founded by Seth, who started his career in pest control in 2014, the company is dedicated to providing professional, effective, and affordable pest control services. As a BBB-accredited business and Nextdoor Neighborhood Favorite, Affordable Pest Solutions LLC offers customized solutions backed by expertise and a commitment to customer satisfaction. Their comprehensive services, including the Yearly 365 Protection Plan, ensure year-round pest prevention for homes and businesses in the area.

Media Contact
Company Name: Affordable Pest Solutions
Contact Person: Sandy Shaljian
Email: Send Email
Phone: (973) 229-9547
Address:22 Carson Rd
City: Budd Lake
State: NJ
Country: United States
Website: https://affordablepestnj.com/

TalentFB Launches “Land Your Dream Job Masterclass” and “Group Coaching Bootcamp” for Accelerated Career Success

TalentFB, a career coaching firm, announces the launch of two new services designed to empower job seekers in today’s competitive market.

These offerings, the “Land Your Dream Job Masterclass” and a 4-week group coaching bootcamp, provide individuals with the tools and strategies needed to stand out and achieve their career goals.

The founder of TalentFB experienced firsthand the challenges of navigating the job market. Early career experiences involved numerous rejections despite dedicated efforts. A pivotal moment involved a strategic approach to connecting with a target company, which resulted in valuable insights about effective job search strategies. These experiences, coupled with a diverse career path involving multiple job changes, highlighted the need for a more effective approach to job searching. The founder observed that many job seekers rely on traditional methods like resume submissions, often overlooking the importance of showcasing unique value and expertise. In a market where recruiters review hundreds of applications, simply having qualifications is not enough.

This realization led to the establishment of TalentFB, with a mission to help professionals navigate the complexities of the job market. The firm aims to equip clients with the tools and strategies necessary for both immediate and long-term career success. TalentFB believes that many career coaching resources offer generic advice without providing truly innovative solutions. The firm’s approach focuses on empowering individuals to differentiate themselves and gain a competitive edge.

The “Land Your Dream Job Masterclass,” an online course, allows individuals to learn at their own pace. It is designed for job seekers and professionals who want a structured approach to their job search. TalentFB will also soon launch a 4-week group coaching bootcamp. This program provides an accelerated learning experience in a collaborative environment where participants can share experiences and learn from each other. This bootcamp is designed for professionals seeking a more intensive and community-driven approach to their job search.

TalentFB’s core values—focus, empowerment, innovation, and collaboration—are central to its coaching philosophy. The firm’s vision is to help individuals maximize their professional potential. The founder recognizes that job seekers often lack the time for extensive trial and error and aims to provide them with the knowledge and resources needed to succeed in a competitive environment.

For more information about TalentFB’s career coaching services, contact frederic@talentfb.net or visit www.frederic-bonifassy.com.

Media Contact
Company Name: TalentFB Pte Ltd
Contact Person: Frederic Bonifassy
Email: Send Email
Phone: +6597250010
Country: Singapore
Website: https://frederic-bonifassy.com/

Metastatic Prostate Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It covers the Metastatic Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Prostate Cancer Pipeline Report to explore emerging therapies, key Metastatic Prostate Cancer Companies, and future Metastatic Prostate Cancer treatment landscapes @ Metastatic Prostate Cancer Pipeline Outlook Report

Key Takeaways from the Metastatic Prostate Cancer Pipeline Report

  • In February 2025:- Bayer:- This study is a phase III multinational, multicenter,randomized, double blind, placebo controlled, study with a randomization allocation ratio of 1:1 (radium-223 dichloride plus abiraterone acetate plus prednisone/prednisolone: placebo plus abiraterone acetate plus prednisone/prednisolone). Until the final overall survival (OS) analysis, the study period consisted of screening / randomization, treatment, active follow-up with clinic visits, active follow-up without clinic visits, and longterm follow-up phases.
  • In February 2025:- AstraZeneca:- This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer. The study consists of 2 parts, Part A and Part B. Part A consists of the dose escalation cohorts and will include patients with metastatic castration resistant prostate cancer (mCRPC) or metastatic castration-sensitive prostate cancer (mCSPC); Part B consists of dose expansion cohorts and will include patients with mCSPC only.
  • In February 2025:- Novartis Pharmceuticals:– The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants have been enrolled in 20 countries.
  • In February 2025:- Aragon Pharmaceuticals Inc.:– This Phase 3 clinical trial is an essential step in the evaluation of an investigational medication to see if it may be useful in treating prostate cancer. The purpose of the SPARTAN study is to compare the safety and effectiveness of the investigational medication to placebo in delaying prostate cancer from spreading to other parts of the body. A placebo is a pill that looks like the investigational medication but does not contain any active medication, a dummy pill.
  • In February 2025:- Janssen Research & Development LLC:- The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate plus low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).
  • In February 2025:- Halda Therapeutics OpCo Inc.:- This is a Phase 1/2, open-label study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of oral single-agent HLD-0915. Patients on the study must continue androgen deprivation therapy (ADT) unless surgically castrated.
  • DelveInsight’s Metastatic Prostate Cancer pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
  • The leading Metastatic Prostate Cancer Companies such as Tavanta Therapeutics, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORIC Pharmaceuticals, Telix Pharmaceuticals (Innovations) Pty Limited, Orion Corporation, OncoC4 Inc., Bristol-Myers Squibb/Ono Pharmaceuticals, Janssen Research & Development LLC, Merck Sharp & Dohme LLC, Modra Pharmaceuticals, Minneamrita Therapeutics LLC, AB Science, Cellbion Co., Ltd., Allarity Therapeutics, Janssen Research & Development, LLC, Hansoh BioMedical R&D Company, Jiangsu HengRui Medicine Co., Ltd., Hinova Pharmaceuticals Inc., ValiRx Plc, Epizyme Inc., Astrazeneca, and others.
  • Promising Metastatic Prostate Cancer Therapies such as Androgen Deprivation Therapy, Docetaxel, Nivolumab, Tazemetostat, Abiraterone/prednisone, Enzalutamide, and others.

Discover how the Metastatic Prostate Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Prostate Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Prostate Cancer Clinical Trials and Studies

Metastatic Prostate Cancer Emerging Drugs Profile

  • TAVT-45: Tavanta Therapeutics

TAVT-45 is a novel oral suspension of abiraterone acetate. It was designed as an alternative abiraterone acetate formulation with clear benefits over branded Zytiga tablets. TAVT-45 granules are rapidly reconstituted in water or juice and easily consumed, which could aid the ~20-30% of patients who have dysphagia or difficulty swallowing.5,6 In clinical studies with TAVT-45, variability in abiraterone exposure was reduced compared to Zytiga, and bioavailability was enhanced in subjects in a fasted state. The improved absorption profile allows for a reduction in the total daily dose of TAVT-45 compared to Zytiga and may potentially improve exposure to therapeutic abiraterone concentrations over 24 h. The large food effect of Zytiga is also avoided, and it is anticipated TAVT-45 to be dosed without regard to meals.

  • Onvansertib: Cardiff Oncology

Onvansertib is a first-in-class, third-generation, oral and highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK1) enzyme, which is over-expressed in multiple cancers including leukemias, lymphomas and solid tumors. Onvansertib targets the PLK1 isoform only (not PLK2 or PLK3), is orally administered and has a 24-hour half-life with only mild-to-moderate side effects reported. Currently, the drug is in Phase II stage of its development for the treatment of prostate cancer.

  • ONCT-534: Oncternal Therapeutics

ONCT-534, Dual-Action Androgen Receptor Inhibitor (DAARI) candidate, is a novel investigational, potentially first-in-class, orally bioavailable, dual-action androgen receptor (AR) inhibitor, designed to treat patients with metastatic castration-resistant prostate cancer and other androgen receptor-driven diseases. Currently, the drug is in Phase I/II stage of its development for the treatment of prostate cancer.

  • VIO-01: Valerio Therapeutics

VIO-01 is designed to abrogate several DNA repair pathways and trigger a robust immune response by activating the innate immune response through the STING pathway. The STING pathway plays a critical role in detecting DNA abnormalities and activating the immune system to target and destroy cancer cells. VIO-01 is currently undergoing proof-of-concept IND-enabling preclinical studies, alone and in combination with cancer immunotherapies. Currently, the drug is in Phase I/II stage of its development for the treatment of prostate cancer.

  • ORIC-944: ORIC Pharmaceuticals

ORIC-944 is a potent, orally bioavailable, highly selective allosteric small molecule inhibitor of PRC2, the complex which tri-methylates histone H3 lysine 27 (H3K27me3) via targeting the embryonic ectoderm development (EED) subunit. Currently, the drug is in Phase I stage of its development for the treatment of prostate cancer.

The Metastatic Prostate Cancer pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Prostate Cancer with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer Treatment.
  • Metastatic Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Metastatic Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Prostate Cancer market.

Get a detailed analysis of the latest innovations in the Metastatic Prostate Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Prostate Cancer Unmet Needs

Metastatic Prostate Cancer Companies

Pharmaceuticals, Telix Pharmaceuticals (Innovations) Pty Limited, Orion Corporation, OncoC4 Inc., Bristol-Myers Squibb/Ono Pharmaceuticals, Janssen Research & Development LLC, Merck Sharp & Dohme LLC, Modra Pharmaceuticals, Minneamrita Therapeutics LLC, AB Science, Cellbion Co., Ltd., Allarity Therapeutics, Janssen Research & Development, LLC, Hansoh BioMedical R&D Company, Jiangsu HengRui Medicine Co., Ltd., Hinova Pharmaceuticals Inc., ValiRx Plc, Epizyme Inc., Astrazeneca, and others.

Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Metastatic Prostate Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Prostate Cancer Therapies and key Metastatic Prostate Cancer Developments @ Metastatic Prostate Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Prostate Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Prostate Cancer Companies- Tavanta Therapeutics, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORIC Pharmaceuticals, Telix Pharmaceuticals (Innovations) Pty Limited, Orion Corporation, OncoC4 Inc., Bristol-Myers Squibb/Ono Pharmaceuticals, Janssen Research & Development LLC, Merck Sharp & Dohme LLC, Modra Pharmaceuticals, Minneamrita Therapeutics LLC, AB Science, Cellbion Co., Ltd., Allarity Therapeutics, Janssen Research & Development, LLC, Hansoh BioMedical R&D Company, Jiangsu HengRui Medicine Co., Ltd., Hinova Pharmaceuticals Inc., ValiRx Plc, Epizyme Inc., Astrazeneca, and others.
  • Metastatic Prostate Cancer Therapies- Androgen Deprivation Therapy, Docetaxel, Nivolumab, Tazemetostat, Abiraterone/prednisone, Enzalutamide, and others.
  • Metastatic Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Metastatic Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Metastatic Prostate Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Prostate Cancer Pipeline Report—access it now! @ Metastatic Prostate Cancer Emerging Drugs and Major Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Prostate Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Prostate Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. TAVT-45: Tavanta Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Onvansertib: Cardiff Oncology
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. VIO-01: Valerio Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Metastatic Prostate Cancer Key Companies
  21. Metastatic Prostate Cancer Key Products
  22. Metastatic Prostate Cancer- Unmet Needs
  23. Metastatic Prostate Cancer- Market Drivers and Barriers
  24. Metastatic Prostate Cancer- Future Perspectives and Conclusion
  25. Metastatic Prostate Cancer Analyst Views
  26. Metastatic Prostate Cancer Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Prostate Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Maffra Cheese Company Announces Exciting New Direct-to-Consumer Model

Renowned Australian cheesemaking company Maffra Cheese Company is happy to announce the introduction of a new direct-to-consumer model scheduled for later this year. This strategic project will provide cheese lovers all around direct access to the award-winning range of the company, therefore strengthening its dedication to provide top quality cheeses right from the farm to the consumer’s table.

Maffra Cheese Company opened in 1870 and has always been the leading edge in Australian cheesemaking. The firm started at Gibney’s Hotel, where a group of farmers set up one of Australia’s first “automated” cheese manufacturers. Under the direction of renowned cheesemaker and chemist Ferial Zekiman today, Maffra keeps creating some of the best cheeses in the nation. Zekiman, awarded an Order of Australia in 2016 for her efforts in the dairy sector, has helped maintain the company’s high standards.

From farm to plate, Maffra Cheese Company supervises every element of the cheesemaking process to guarantee that every product reflects the company’s dedication to excellence. The cows live in a clean, low-stress environment and their feed and pasture are carefully turned to keep ideal milk quality all year long. This emphasis on sustainable methods and quality control produces cheeses reflecting the special seasonal character of the farm in addition to being quite delicious.

The new direct-to-consumer approach will make Maffra’s handcrafted cheeses more easily available to consumers so they can quickly order their preferred items online. Maffra’s cheeses will be ready with just a few clicks, whether for thoughtful presents or entertaining visitors. As it is ready to present the best cheeses from Gippsland straight to homes all around, the company asks cheese-lovers to stay tuned for further information.

About Maffra Cheese Company

Based in Gippsland, Victoria, Maffra Cheese Company has received many international medals for artisan cheeses. The business is still committed to creating premium seasonal cheeses that honor Australia’s rich cheesemaking past.

Media Contact
Company Name: Maffra Cheese Company
Contact Person: Jack
Email: Send Email
Country: Australia
Website: https://maffra.designpointstaging.com.au/

myBVICharter Proudly Presents Award-Winning Charter Yachts in the British Virgin Islands

myBVICharter, with operational headquarters in both the British Virgin Islands and the U.S. Virgin Islands, is a leading yacht charter company that boasts an impressive fleet of over 400 yachts. Operating under the umbrella of DMA Yachting, the renowned charter company is thrilled to introduce its portfolio of award-winning charter yachts offering unparalleled levels of luxury and individualized experiences in the breathtaking British Virgin Islands (BVI).

The British Virgin Islands is known for its crystal-clear waters, secluded beaches, and vibrant marine life, making it a haven for sailing enthusiasts and lovers of luxury alike. myBVICharter strives to make each voyage an unforgettable adventure with excellent service and customized itineraries. From power catamarans to sleek motor yachts, myBVICharter’s award-winning fleet features a diverse range of vessels tailored to meet the preferences of discerning travelers

Showcasing a selection of myBVICharter’s Award-Winning Yachts

OLIVIA CHARLES—Catamaran: This spacious crewed catamaran has four cabins, perfect for eight guests. It features plenty of seating and even a small bar, making it perfect for relaxing.

According to myBVICharter, Olivia Charles Catamaran swept the awards at the 2024 BVI Yacht Show, taking home 1st Place for Best Designer Water, 1st Place for Best Dessert, and Runner-Up for Best Yacht in Show (54-59 ft). “Emma Clark’s Designer Water won 1st Place in the Best Designer Water Competition at the BVI Yacht Show 2024. Her award-winning water was served in a martini glass with fresh mint, a giant ice cube slowly releasing fruity sweetness, and a bubble on top that popped with a delicate puff of smoke,” said Daniel Asmus, owner of DMA Yachting.

OMAKASE—Power Catamaran: This impressive 68-foot charter yacht, which placed 1st Place for Best Motor Yacht in Show, is classified primarily as a power catamaran. It features 3 generous cabins with stylish décor, great ensuite facilities, and unbeatable views in the morning, easily accommodating a group of 6 guests. Its massive flybridge is well-protected, has a balcony towards the bow, and a big aft deck with sunbeds. Moreover, there are a variety of seating areas where guests can spend most of their time.

ANGELEYES—Motor Yacht: This stunning yacht has won many awards on Netflix. According to the company, Angeleyes is amazing not just because of its beauty but also because of the overall experience created by the fantastic crew. Angeleyes is the perfect choice for guests looking to experience the most fun and luxury possible on a Caribbean charter.

myBVICharter, powered by DMA Yachting, proudly boasts an impressive 4.9-star customer satisfaction rating on Trust Point. Customers consistently praise the seamless booking process, the exceptional staff, the unforgettable experiences, the personalized itineraries, the diverse fleet of luxury yachts, and the breathtaking destinations. This outstanding rating is a true reflection of myBVICharter’s commitment to excellence and delivering world-class yachting adventures.

The yacht charter company values the way it does business, with transparency and honesty at the center of its core. “We are who we are today because of our incredible customers. Our goal is to make everyone’s experience unforgettable,” added Daniel Asmus.

myBVICharter offers attentive customer service, smooth and straightforward booking, and an attentive and professional team. myBVICharter’s positive feedback points out its dedication to making yacht charting approachable and without headaches for its adventurous travelers.

Please visit myBVICharter’s website for more details on its award-winning charters or to reserve any of its exclusive crewed or captain-only charters.

About myBVICharter

Powered by DMA Yachting, myBVICharter is a leading provider of yacht charters in the British Virgin Islands and the U.S. Virgin Islands. With an aim for excellence and a passion for delivering memorable experiences to its customers, the company works with an extensive network of suppliers that offer various exclusive yacht options to cater to every traveler’s unique preference and budget. myBVICharter’s professional team is adept at scrutinizing every aspect of a yacht to ensure it meets its high standards. They also assess the flexibility of the menu, the dynamics among the crew, and how family-friendly the yacht is. Focusing on attention to detail and exceptional customer satisfaction, myBVICharter yacht charter continues to set the benchmark for excellence in the yacht charter industry.

Media Contact
Company Name: MyBVICharter
Contact Person: Daniel Asmus
Email: Send Email
Country: United States
Website: https://mybvicharter.com/

Bunker Fuel Market is Anticipated is Reach $181.64 Billion by 2032 with a Steady CAGR of 4.30%

“Bunker Fuel Market”
Bunker fuel is a mixture of fuel oils used in marine vessels to keep engines running. It is poured into the ship’s bunkers and can be in several forms, including high-sulfur fuel oil, low-sulfur fuel oil, and diesel oil.

The bunker fuel market, a critical component of the global maritime industry, has undergone significant transformations in recent years. Driven by regulatory changes, environmental concerns, and shifting energy dynamics, the market for bunker fuel—the fuel used by ships—has seen both challenges and opportunities emerge.

Bunker fuel Market Size was valued at USD 124.35 billion in 2023. The Bunker fuel industry is projected to grow from USD 129.69 Billion in 2024 to USD 181.64 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.30 % during the forecast period (2024 – 2032).

Bunker fuel is the lifeblood of the shipping industry, powering vessels that transport over 80% of global trade by volume. Traditionally, the market has been dominated by heavy fuel oil (HFO), a residual product of crude oil refining. However, the introduction of the International Maritime Organization’s (IMO) 2020 sulfur cap regulation marked a turning point for the industry. The regulation limited the sulfur content in marine fuels to 0.5%, down from the previous 3.5%, forcing shipowners to adopt cleaner fuels or install exhaust gas cleaning systems (scrubbers).

The market is segmented into various fuel types, including:

  1. Very Low Sulfur Fuel Oil (VLSFO): The most widely used bunker fuel post-IMO 2020, VLSFO has become the standard for compliance with sulfur regulations.
  2. Marine Gas Oil (MGO): A distillate fuel with low sulfur content, MGO is used primarily in emission control areas (ECAs).
  3. High Sulfur Fuel Oil (HSFO): Still used by vessels equipped with scrubbers, HSFO remains a cost-effective option for some shipowners.
  4. Alternative Fuels: Liquefied natural gas (LNG), biofuels, methanol, and hydrogen are gaining traction as the industry seeks to reduce greenhouse gas emissions.

 

Market Segmentation

The global bunker fuel market has been segmented into fuel, application, and seller.

Based on fuel, the market has been segmented into high-sulfur fuel oil (HSFO), very-low-sulfur fuel oil (VLSFO), marine diesel oil (MDO), and liquefied natural gas (LNG). The very-low sulfur fuel oil (VLSFO) segment accounted for the largest share of the market in 2025. It is sensitive to the environment. It only has a 0.1% sulfur content. Most ship owners have selected it as the proper fuel after considering environmental restrictions and emission standards. The growth of worldwide commerce has increased the demand for marine gasoline. The most cost-effective alternative is bunker fuel, which supports the maritime sector. On the other hand, the marine diesel oil (MDO) segment was the fastest-growing segment during the forecast period owing to its cheapest cost.

Based on application, the market has been segmented into bulk & general cargo fleet, tanker fleet, container fleet, and others (including passenger ferries and cruise ships). The container fleet accounted for the largest revenue share in 2025 in the bunker fuel market. The rise in trade-related agreements and the demand for cargo transportation via ships explains this. The tanker fleet was the fastest-growing segment because most of the transportation of goods was carried out through bulk and general cargo vessels.

Based on seller, the market has been segmented into major oil companies, leading independent sellers, and small independent sellers. The major oil companies segment accounted for the largest revenue share in 2025 in the market for bunker fuel. The global hegemony of the oil majors in chartering crude oil tankers is credited with this expansion. On the other hand, leading independent sellers was the fastest-growing segment. These distributors have a variety of physical assets, including storage terminals and blending facilities in significant bunkering ports. They can outperform smaller independent distributors because of this.

 

Get Report Sample Copy: https://www.marketresearchfuture.com/sample_request/10871

 

Key Companies in the Bunker fuel market include

 

Chemoil Energy Limited (Hong Kong)

Aegean Marine Petroleum Network, Inc. (Switzerland)

World Fuel Services Corporation (US)

Gulf Agency Company Ltd. (Dubai)

Gazpromneft Marine Bunker LLC (Russia)

BP Marine Ltd. (UK)

 

Buy Now: https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=10871

 

Company News and Developments

Shell’s Expansion into LNG Bunkering Shell, one of the world’s largest bunker fuel suppliers, has been at the forefront of the transition to cleaner fuels. In 2023, the company announced plans to expand its LNG bunkering infrastructure, with new facilities in key ports across Europe and Asia. Shell has also partnered with major shipping companies to promote the adoption of LNG as a marine fuel.

BP’s Investment in Biofuels BP has been actively investing in biofuels as part of its strategy to decarbonize the shipping industry. In early 2023, the company launched a new biofuel blend specifically designed for marine use. The blend, which combines traditional bunker fuel with sustainable biofuels, has been well-received by shipowners seeking to reduce their carbon emissions.

Maersk’s Methanol-Powered Vessels Danish shipping giant Maersk has made headlines with its commitment to methanol as a sustainable fuel. In 2023, the company took delivery of its first methanol-powered container ship, marking a significant milestone in the industry’s transition to alternative fuels. Maersk has also signed agreements with fuel producers to secure a steady supply of green methanol.

TotalEnergies’ Digital Bunkering Platform TotalEnergies has launched a digital platform to simplify the bunker fuel procurement process. The platform, which uses blockchain technology, allows shipowners to track fuel deliveries in real-time and verify the quality and quantity of fuel received. This innovation is expected to enhance transparency and reduce disputes in the bunker fuel market.

Chevron’s Collaboration on Hydrogen Fuel Chevron has partnered with several technology companies to explore the potential of hydrogen as a marine fuel. In 2023, the company announced a pilot project to test hydrogen fuel cells on a commercial vessel. While hydrogen is still in the early stages of development for maritime use, it holds promise as a zero-emission fuel for the future.

 

Related Report

Automotive Coolant Market Research Report – Global Forecast by 2034

Fluorspar Market Research Report – Global Forecast by 2034

Syngas Market Research Report – Global Forecast by 2034

Sodium Methylate Market Research Report – Global Forecast by 2034

Coal Tar Pitch Market Research Report – Global Forecast by 2034

Ultra-Fine Copper Powder (99.9999%) Market Research Report – Global Forecast by 2034

 

About Market Research Future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services. The MRFR team have a supreme objective to provide the optimum quality market research and intelligence services for our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments enable our clients to see more, know more, and do more, which help to answer all their most important questions.

 

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,

5Th Floor, New York,

New York 10013

United States of America +1 628 258 0071

Email: sales@marketresearchfuture.com

 

 

Media Contact
Company Name: Market Research Future
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.marketresearchfuture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bunker Fuel Market is Anticipated is Reach $181.64 Billion by 2032 with a Steady CAGR of 4.30%